- Scinai Immunotherapeutics Ltd. has received expanded support from the Israel Innovation Authority for a robotic aseptic fill & finish platform, with total grant funding of NIS 5 million over two years.
- Approximately 66% of the funding is non-dilutive, with system validation targeted for the third quarter of 2026.
Scinai Immunotherapeutics Ltd. has announced that its project to advance a robotic aseptic fill & finish platform has received expanded support from the Israel Innovation Authority (IIA). The company will now utilise the full approved grant budget of NIS 5 million over two years, with approximately 66% provided as non-dilutive funding.
The programme supports the acquisition and validation of a fully automated robotic-arm aseptic fill & finish system designed to align with EU GMP Annex 1 standards. Validation of the system is targeted for completion in the third quarter of 2026. The investment forms part of Scinai’s broader strategy to expand and modernise its CDMO and contract manufacturing capabilities following its acquisition of Recipharm Israel Ltd. and a commercial collaboration agreement with Recipharm.
The robotic aseptic processing system is intended to reduce human intervention in sterile manufacturing, enhance reproducibility and strengthen contamination control. The system is expected to expand clinical manufacturing capabilities at Scinai’s Jerusalem biologics facility. Together with the Yavne small-molecule site, the company now operates an integrated two-site development and manufacturing platform.
“The expanded support from the Israel Innovation Authority strengthens our ability to invest in next-generation sterile manufacturing capabilities while maintaining disciplined capital allocation.”
Amir Reichman, Chief Executive Officer of Scinai
The company stated it is also monitoring the potential launch of a new IIA programme aimed at supporting industrial capital expenditure investments, subject to approval of Israel’s 2026 state budget.
